Φορτώνει......
Soluble CD105 is prognostic of disease recurrence in prostate cancer patients
While the overall five-year survival rate for prostate cancer is near 100%, up to 35% of patients will develop recurrent disease. At the time of prostatectomy, prostate specific antigen (PSA) is used to guide primary therapy with the goal of curative intervention. It can be valuable to know when pri...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Endocr Relat Cancer |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2020
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7002242/ https://ncbi.nlm.nih.gov/pubmed/31648185 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/ERC-19-0370 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|